PMID- 36702204
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230404
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 29
IP  - 5
DP  - 2023 May
TI  - Analysis of the risk factors and prognosis for severe fever with thrombocytopenia 
      syndrome associated encephalopathy.
PG  - 464-468
LID - S1341-321X(23)00022-3 [pii]
LID - 10.1016/j.jiac.2023.01.014 [doi]
AB  - OBJECTIVE: Severe fever with thrombocytopenia syndrome (SFTS) is frequently 
      associated with neurological injury, but there are currently few relevant 
      studies. The goal of this study was to look at the risk factors for 
      SFTA-associated encephalopathy (SFTSAE) and the short- and long-term prognosis of 
      such patients. METHODS: We retrospectively studied 145 patients with SFTS who 
      were treated at our hospital between May 2019 and November 2021. Clinical 
      characteristics were collected, and patients were divided into two groups based 
      on whether there was neurological injury during the disease: SFTSAE group and 
      non-SFTSAE group. Univariate analysis was used to compare the differences in 
      clinical data and outcomes between two groups, and multivariate Logistic 
      regression analysis was used to reveal the independent risk factors for SFTSAE, 
      and the predictive efficacy was assessed using the receiver operating 
      characteristic (ROC) curve. Furthermore, survivors of SFTSAE were contacted by 
      phone 6 months after discharge to assess the case fatality rate and quality of 
      life. RESULTS: The prevalence of SFTSAE was 22.7% (33/145). Bleeding symptoms, 
      D-dimer level and blood amylase level were all independent risk factors for 
      SFTSAE (P < 0.05). The combined AUC of these three factors was 0.969. Patients 
      with SFTSAE had a 45.4% in-hospital mortality rate, and survivors had a largely 
      normal quality of life after discharge. CONCLUSION: Patients with SFTSAE 
      frequently have multiple organ dysfunction, a high mortality rate, and a 
      favorable long-term prognosis for survivors. Clinical manifestations of bleeding 
      symptoms, elevated serum amylase, and elevated D-dimer were all independent risk 
      factors for SFTSAE.
CI  - Copyright (c) 2023 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Youdong, Xu
AU  - Youdong X
AD  - Department of Intensive Care Unit, Affiliated Lu'an Hospital, Anhui Medical 
      University, Lu'an, 237000, China.
FAU - Xiaofeng, Du
AU  - Xiaofeng D
AD  - Department of Intensive Care Unit, Affiliated Lu'an Hospital, Anhui Medical 
      University, Lu'an, 237000, China.
FAU - Xiyuan, Niu
AU  - Xiyuan N
AD  - Department of Intensive Care Unit, Affiliated Lu'an Hospital, Anhui Medical 
      University, Lu'an, 237000, China.
FAU - Zhengdong, Liu
AU  - Zhengdong L
AD  - Department of Intensive Care Unit, Affiliated Lu'an Hospital, Anhui Medical 
      University, Lu'an, 237000, China. Electronic address: lzdys@126.com.
LA  - eng
PT  - Journal Article
DEP - 20230124
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - EC 3.2.1.- (Amylases)
SB  - IM
MH  - Humans
MH  - *Severe Fever with Thrombocytopenia Syndrome
MH  - Retrospective Studies
MH  - Quality of Life
MH  - *Brain Diseases/epidemiology
MH  - Prognosis
MH  - Risk Factors
MH  - ROC Curve
MH  - Amylases
MH  - *Phlebovirus
OTO - NOTNLM
OT  - Encephalopathy
OT  - Prognosis
OT  - Risk factors
OT  - Severe fever with thrombocytopenia syndrome
COIS- Declaration of competing interest Xu Youdong, Du Xiaofeng, Niu Xiyuan, Jun Yuan, 
      Liu Zhengdong declare that they have no conflict of interest.
EDAT- 2023/01/27 06:00
MHDA- 2023/04/04 06:42
CRDT- 2023/01/26 19:22
PHST- 2022/10/11 00:00 [received]
PHST- 2022/12/30 00:00 [revised]
PHST- 2023/01/21 00:00 [accepted]
PHST- 2023/04/04 06:42 [medline]
PHST- 2023/01/27 06:00 [pubmed]
PHST- 2023/01/26 19:22 [entrez]
AID - S1341-321X(23)00022-3 [pii]
AID - 10.1016/j.jiac.2023.01.014 [doi]
PST - ppublish
SO  - J Infect Chemother. 2023 May;29(5):464-468. doi: 10.1016/j.jiac.2023.01.014. Epub 
      2023 Jan 24.